HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Market News Stocks News ETF News Crypto News

EyePoint Pharmaceuticals, Inc.

Contributing Author

Recent Articles by EyePoint Pharmaceuticals, Inc.

15 hours
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT -11.10% GlobeNewswire
Nov-03
EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
Oct-29
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 EYPT GlobeNewswire
Oct-16
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Oct-14
EyePoint Announces Pricing of Public Offering EYPT GlobeNewswire
Oct-14
EyePoint Announces Proposed Public Offering of Common Stock EYPT GlobeNewswire
Oct-14
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema EYPT GlobeNewswire
Sep-16
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Aug-26
EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
Aug-18
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Aug-06
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference EYPT GlobeNewswire
Aug-06
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Jul-30
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 EYPT GlobeNewswire
Jul-29
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration EYPT GlobeNewswire
Jul-16
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Jun-16
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-28
EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-27
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration EYPT GlobeNewswire
May-16
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-13
EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-07
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.